论文部分内容阅读
目的 :探讨测定血清基质金属蛋白酶 - 9(MMP - 9)的含量对诊断卵巢上皮癌的价值及它与患者预后的关系。方法 :将卵巢上皮癌 (OEC) 43例 ,卵巢交界性肿瘤(BOT) 12例及卵巢良性肿瘤 (OBT) 2 4例分为 3个研究组 ,2 0例正常妇女为对照组 ,用ELISA法测定各组术前血清中的MMP - 9含量。结果 :(1)OEC、OBT、BOT及对照组血清MMP - 9的中位数分别为 534.6 0、2 79.19、2 0 0 .54、55.56ng L ,上述各组的范围分别为 111.18～ 176 6 .12ng L、16 .38～ 874 .34ng L、2 5.10～ 4 2 3.2 9ng L、11.0 1～ 2 0 1.6 3ng L。OEC组血清MMP - 9水平高于OBT、BOT及对照组 ,差异有显著性 (P <0 .0 5) ;(2 )OEC患者按临床分期、病理分级、组织学类型、淋巴或大网膜转移等影响患者预后的因素分组 ,各组间血清MMP - 9水平无显著性差异。结论 :患者血清MMP - 9水平与卵巢肿瘤的恶性行为有关 ,对诊断有一定的价值 ,但用于判断患者预后的价值有限
Objective: To investigate the value of serum matrix metalloproteinase - 9 (MMP - 9) in the diagnosis of ovarian epithelial carcinoma and its relationship with prognosis. Methods: 43 cases of ovarian epithelial carcinoma (OEC), 12 cases of borderline ovarian tumor (BOT) and 24 cases of ovarian benign tumor (OBT) were divided into 3 groups and 20 normal women as control group. The preoperative serum MMP - 9 levels were determined. Results: (1) The median serum MMP - 9 levels of OEC, OBT, BOT and control group were 534.60, 2 79.19, 2 054 and 55.56 ng L, respectively, ranging from 111.18 to 176 6 .12 ng L, 16.38 - 874 .34 ng L, 2 5.10 - 4 2 3.2 9 ng L, 11.0 1 ~ 2 0 1.6 3 ng L. The level of serum MMP - 9 in OEC group was higher than that in OBT, BOT group and control group (P <0.05). (2) According to clinical stage, pathological grade, histological type, lymphoid or omental Metastasis and other factors affecting the prognosis of patients in groups, serum MMP - 9 levels between the groups showed no significant difference. Conclusion: The serum level of MMP - 9 in patients is related to the malignant behavior of ovarian tumors and has some value in diagnosis, but the value of judging the prognosis of patients is limited